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Abstract
Background: Patients with visual snow syndrome (VSS) describe tiny flickering dots in the entire visual field resembling
the noise of a poorly adjusted channel of analogue television with additional symptoms. Little is known about the
pathophysiology and therapeutic options for this debilitating condition. Objectives: We present a case series of three
patients with VSS taking mirtazapine, one of the most often prescribed antidepressants, and discuss the utility of anti-
depressants by reviewing our current understanding of pathophysiology and therapy. Results: Mirtazapine has no effect
on VSS, neither positive nor negative. This is in line with the reports from the literature suggested only some beneficial
effects from lamotrigine. Conclusions: Since the pathophysiology of VSS is not fully understood, we still rely on the
reports of individual cases or patient series. This includes not only the positive, but also the negative results to avoid
unnecessary treatment trials. Looking into the literature, antidepressants do not seem to be a solution for the visual
symptoms. So far, best data exists for the anticonvulsant lamotrigine.
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Introduction
The main symptom of visual snow syndrome (VSS) is
visual snow (VS), which patients describe as tiny flickering
dots in the entire visual field resembling the noise of a
poorly adjusted channel of analogue television, that is,
TV-static. Patients have additional visual symptoms
(Table 1) including palinopsia (afterimages), enhanced
entoptic phenomena, such as floaters or blue field phenom-
enon, persistent photophobia, and impaired night-vision
(nyctalopia). After the first publication of clinical criteria
for VSS in 2014,2 both interest in and understanding of the
disease are steadily growing. Still little is known about the
pathophysiology and therapeutic options for this debilitat-
ing condition.
So far, the etiology of VSS is not fully understood. In the
vast majority of patients, no structural cause could be found in
the ophthalmological and neurological examination and the
encephalographic paraclinical tests, visual evoked potentials,
and brain imaging or standard laboratory.3–6 However, occa-
sionally, secondary causes can be identified, such as Creutz-
feldt–Jakob disease or stiff-person syndrome.7,8
Although VSS is of benign character in respect of visual
acuity and visual field, the impact on patients’ live can be
disastrous. Until now, most publications on VSS treatment
options are case reports or case series with only one retro-
spective cohort study.9
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In a previous study of 78 patients, 68 (87%) had a his-
tory of headache with 48 fulfilling migraine criteria (62%).
Eleven (14%) had symptoms of depression according to a
Patient Health Questionnaire (PHQ)-8 above 10 points.2 In
a retrospective analysis of 58 patients, lifetime depression
occurred in 41%, comorbid migraine in 52%.9 One there-
fore might expect that antidepressants would have some
effect on VSS.
Here, we present case report of three patients with VSS
taking mirtazapine, one of the most often prescribed anti-
depressants.10 Mirtazapine has so far not been mentioned
for VSS, and we will discuss its utility in the context of
current opinions on pathophysiology and therapy.
Cases
All three patients had already started mirtazapine prior to
presenting to our study for depression or sleep disturbance.
Although depression was officially diagnosed only in two,
all had a history of depression and two were still showing
symptoms. As part of our clinical routine, all patients are
asked about their current and previous medication for VSS
and other indication. If the patient stated a positive effect
on VSS, we asked in more detail which symptoms had
improved. In addition, we assess whether the symptoms
of the main indication improved; for depression, we use
PHQ-8 for quantification with a score greater than 10 indi-
cating major depression.11
Case 1 was a 28-year-old female suffering from VSS for
2 years and comorbid migraine with aura since puberty.
Besides VS, the patient described floaters, photophobia,
tinnitus, loss of concentration, and irritability. The second
most disturbing after VS was her increased sensitivity to
light in all environments, especially to artificial lights. Mir-
tazapine was taken up to 30 mg, at presentation with 15 mg
for 2 years for sleeping problems. The sleep improved, but
there was no effect on VSS. The patient also suffered from
a depressive syndrome with a PHQ-8 of 20 points although
this was not officially diagnosed. There was no additional
medication or any pharmaceutical trial before.
Case 2 was a 22-year-old female suffering from VSS for
6 years. She did not have migraine. Besides VS, the patient
described floaters, bright flashes, blue field entoptic phe-
nomena with little cells and swirls, nyctalopia, photopho-
bia, tinnitus, and irritability as well as lethargy. After VS,
the patient ranked tinnitus as the second most disturbing
symptom. She additionally had a diagnosis of depression
for 2 years and started taking mirtazapine 30 mg 4 months
ago, without an impact on mood but improved sleep. The
patient still had a PHQ-8 of 15 points. There was an addi-
tional pharmaceutical trial before with St. John’s wort
showing no effect on VSS. There was no other concomitant
medication.
Case 3 was a 34-year-old male suffering from VSS for
19 years. There was no history of migraine. Besides VS, the
patient described palinopsia, floaters, nyctalopia, photo-
phobia, tinnitus, loss of concentration, and irritability as
well as lethargy. Additionally, the patient had the feeling
of derealization, which he ranked as disturbing as VS itself.
He took mirtazapine 30 mg for 8 years because of an initial
depressed mood, showing an impact on mood and accep-
tance but not on VSS. At presentation, the patient did not
suffer from depression as reflected in a PHQ-8 of 9 points.
The patient stated that alcohol consumption could worsen
VSS in intensity. There was no other concomitant
medication.
Discussion
In our case series, mirtazapine was not helpful for the treat-
ment of VSS. As long as we have not fully understood the
pathophysiology of VSS, we will depend mainly on reports
of case series or individual reports, including not only pos-
itive but also negative results.
Mirtazapine has a dual mechanism that affects both
adrenergic 2-receptors (auto- and hetero) and serotonergic
receptors (5-HT2 and 5HT3) resulting in a release of nor-
epinephrine and serotonin. This is also the explanation for
its successful use in depression, being its main but not only
clinical indication besides anxiety and sleeping disorders.
The latter one is mainly distributed by its potent activity as
a strong inverse agonist of the histamine H1 receptor.
12,13
The transmitters involved in VSS are so far unknown, but
our data suggest that norepinephrine and serotonin might
not be of particular relevance.
When it is not norepinephrine or serotonin, what could
then be the mechanism behind VSS? There is still no
straight answer, but we will briefly discuss here the current
understanding of pathophysiology and treatment options of
this condition.
Pathophysiology
The key feature of VSS is its stereotypic presentation that
underscores that it is a unique clinical condition.2,14,15 Its
main symptom, VS, that is, persistent visual noise, is not
limited to a specific part of the visual field and clearly does
not follow retinotopy. It rather covers the entire visual field,
Table 1. Visual snow syndrome criteria (ICHD-III A 1.4.6).1
A. Dynamic, continuous, tiny dots across the entire visual field,
persisting for >3 months
B. Additional visual symptoms of at least two of the following
four types:
1. Palinopsia
2. Enhanced entoptic phenomena
3. Photophobia
4. Impaired night vision (nyctalopia)
C. Symptoms are not consistent with typical migraine visual aura
D. Symptoms are not better accounted for by another disorder
ICHD: International Classification of Headache Disorders.
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making it less possible to be caused by migraine aura.2,14,16
More likely, the origin should be located somewhere at or
behind the lateral geniculate nucleus when visual infor-
mation merges from both eyes for the first time.15,17,18
However, the focus in interpreting VSS should not be
solely on the static but also on the syndrome-defining
accompanying symptoms like palinopsia, enhanced
entoptic phenomena, and photophobia that might better
be explained by a more general visual processing deficit
than just by a structural one.2,5,18
A dysfunction of higher order visual processing comes
from the first functional neuroimaging study using
fluorodeoxyglucose–positron emission tomography
(18F-FDG–PET) in 17 VS patients and 17 controls show-
ing hypermetabolism in the right lingual gyrus.19 Electro-
physical studies using visual evoked potentials showed
significantly prolonged N145 latency in 18 patients with
VSS pointing to the visual association cortex,18 with normal
P100 latency and amplitude reflecting a normal functioning
visual pathway anterior to the primary visual cortex. How-
ever, there is also conflicting data suggesting rather involve-
ment of the primary visual cortex than the association cortex
due to loss of habituation of repetitive visual evoked poten-
tials, lowered phosphene thresholds, reduction in gamma-
band power, and a dysfunction in visual tasks specific for
the primary visual cortex but not for the association cor-
tex.20–23 Additionally, there is a more global thinking of
VS being a disorder of sensory processing which might
explain the involvement of other modalities, such as hearing
with highly comorbid tinnitus; or a more localized theory of
thalamocortical dysrhythmia based on an imbalance
between the konio- and magnocellular pathway.17 This dis-
turbance further could be sustained by a cortical trigger, for
example, the discussed cortical hyperexcitability.17,24
Worth to discuss is the model of stochastic resonance
considered by Metzler et al. using the whole VSS in all its
facets, that is, combining common visual and nonvisual
symptoms.1,17,19,25 Briefly, it is based upon the knowledge
that the addition of just a little noise sharpens the sensory
system to better detect low-threshold content, even
between various sensory inputs. Accordingly, this would
explain the involvement of other sensory disturbances, such
as photophobia, tinnitus or entoptic phenomena.25 Impor-
tantly, the suffering from each of these can exceed the
suffering from VS itself. Photophobia, for instance, reaches
the levels in VSS comparable to those of chronic migrai-
neurs during attacks but is present on a continuous basis.26
VSS seems to be tenacious to treat. However, some of
the accompanying visual or nonvisual symptoms might be
better accessible for treatment.
Treatment
So far, there is no reliable treatment for VSS, and to the best
of our knowledge, we derive conclusions from small case
series and experience with migraine aura. Our limited
understanding of the pathophysiology of VSS hinders the
conduction of targeted randomized trials. Further, VSS just
gets newly recognized as an entity on its own, with a grow-
ing interest not only what could be done in the future but
also what has been done unknowingly in the past. Follow-
ing this question, the first data from a retrospective cohort
analysis came from van Dongen et al. who described a
cohort of 58 patients with VSS. Of these, 29 were treated.9
The medication most often tried was lamotrigine being
partially effective in 5 of 26 without a complete remission,
followed by topiramate (partially effective in 1 of 4). Inef-
fective were valproate in seven patients, acetazolamide in
two patients, and flunarizine in one patient. In one case
report, a complete remission was described for valproate.27
Another patient improved by taking lamotrigine. The
authors speculate that this effect might be due to the nor-
malization of an initially decreased habituation of repeti-
tive visual evoked potentials, but an effect of comorbid
migraine cannot be ruled out.20 Other occasional effective
treatments in case reports were baclofen, naproxen, propra-
nolol, sertraline, and verapamil.2,19,28,29
Some patients with VSS do not try pharmacological
treatment as also reflected in the retrospective cohort study
from van Dongen et al.9 This might be due to the lack of
understanding of the mechanism of VSS resulting in poten-
tial concerns about the possible worsening of the symp-
toms. So far, only amitriptyline and topiramate have
reportedly been associated with worsening VSS.19
Lauschke et al. offered a non-pharmaceutical approach
by using tinted lenses mostly in the blue–yellow spectrum
that gave 11 of the 12 patients relief and supports the theory
of thalamocortical dysrhythmia.17
It is interesting that there are nearly no reports on the use
of antidepressants for VSS, considering the impact of VSS
on mood and anxiety. That is even more remarkable in the
context of mirtazapine being one of the most frequently
described antidepressants in Germany in the last years.10
As patients with VSS are often misinterpreted within the
framework of psychogenic disorders, the number should be
even higher. One potential explanation could be that mir-
tazapine was indeed used, but without effect, and thus has
not been judged worth reporting.
Limitations
One limitation is that VSS has not been assessed prior to
starting treatment with mirtazapine, as the medication was
already taken before presenting to us for the first time.
Therefore, some slight improvement might have been over-
seen. Additionally, we depended more on subjective
impression than on objective data as there is so far no
clinical tool to assess VSS symptoms as regards quantity
or quality. Another point is that mirtazapine was taken only
up to 30 mg/day, thus we cannot rule out that higher doses
could be helpful as it is known that mirtazapine shows a
dose-dependent effects, where at higher plasma levels the
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antihistaminic effect decreases while the noradrenergic
effect increases.12
Conclusion
VSS keeps it secrets, and there is still no ideal medical
approach. The best data exist for lamotrigine, which there-
fore could be discussed off-label with patients. Despite
VSS having high impact on patients’ mood, antidepressants
do not seem to be a solution for the visual symptoms. VSS
deserves more attention, and we encourage physicians to
not only present medications helpful but also the ones being
unsuccessful to avoid unnecessary trials in other patients.
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37: 722–727.
7. Piquet AL, Khan M, Warner JEA, et al. Novel clinical fea-
tures of glycine receptor antibody syndrome. Neurol Neu-
roimmunol Neuroinflamm; 6. Epub ahead of print 1 July
2019. DOI: 10.1212/NXI.0000000000000592.
8. Chen BS, Lance S, Lallu B, et al. Visual snow: not so benign.
J Clin Neurosci 2019; 64: 37–39.
9. van Dongen RM, Waaijer LC, Onderwater GLJ, et al. Treat-
ment effects and comorbid diseases in 58 patients with visual
snow. Neurology 2019; 93: e398.
10. Schwabe U, Paffrath D, Ludwig W-D, et al.
Arzneiverordnungs-Report 2019. Berlin, Heidelberg:
Springer, https://public.ebookcentral.proquest.com/choice/
publicfullrecord.aspx?p¼5905249 (2019, accessed 8 Febru-
ary 2020).
11. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a
measure of current depression in the general population.
J Affect Disord 2009; 114: 163–173.
12. Anttila SAK and Leinonen EVJ. A review of the pharmaco-
logical and clinical profile of mirtazapine. CNS Drug Rev
2001; 7: 249–264.
13. Benkert O and Hippius H (eds). Kompendium der Psychia-
trischen Pharmakotherapie. 12., vollständig überarbeitete
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